Contura

Pioneering, proven pain treatment for knee OA

Arthrosamid® — The first and only synovial scaffold administered via a single injectable for long-lasting pain relief.

Adobe Stock 506953633

About 528 million

people worldwide were living with osteoarthritis in 2019; an increase of 113% since 1990.

The Problem

Despite osteoarthritis (OA) being the most common type of arthritis and the fastest-growing cause of disability worldwide,  the treatment area has seen minimal progression in the last 20 years. With so little known about exactly what causes knee OA, a permanent cure has yet to be discovered.

Redefining treatment for knee OA, without surgery

Arthrosamid® is a non-biodegradable 2.5 iPAAG injectable implant that delivers long-lasting pain relief — improving the quality of life for patients with knee OA.

Adobe Stock 351385205
Long lasting icon

Pioneering

Arthrosamid® is a first-in-class synovial scaffold delivered as a single, minimally invasive out-patient procedure performed under local anaesthesia, with ultrasound guidance.

Without surgery icon

Proven

Researched for more than two decades, Arthrosamid® has been proven to maintain a statistically significant reduction in pain in patients with knee OA 3 years after treatment.

Proven icon

Pain Relief Treatment

A single, minimally invasive, long-lasting knee OA treatment, Arthrosamid® has demonstrated an improvement in quality of life with patients in clinical trials reporting a reduction in pain by Week 4 — and lasting over 3 years.

OSP ARTHROSAMID 0454 copy

10,000+ patients

Arthrosamid® has treated more than 10,000 patients and is available in over 200 clinics across Europe.

Simple one-step outpatient procedure

Relieve pain and improve the function of the knee affected by knee OA, with a simple, one-step outpatient procedure.

Our Results

In all our studies , Arthrosamid® exceeds the MCID of 9 points and improvement is maintained up to 3 years after a single injection.

Grouped studies

WOMAC pain subscale change from baseline across studies

344 million people living with osteoarthritis experience severity levels (moderate or severe) that could benefit from rehabilitation.

P1600747 00 00 17 06 Still003

Patient Rehabilitation Programme

We are delighted to introduce our patient rehabilitation programme. Click on the link below to see the videos.

We use cookies to give you the best online experience. By agreeing, you accept the use of cookies in accordance with our cookie policy.